2023 Volume 38 Issue 2 Pages 101-106
The Clinical Practice Guidelines for Pancreatic Cancer 2022 were revised in July 2022. In the new edition, 3 clinical questions (CQs) were described in "general statements" as background questions, while 10 CQs including 5 on "precision medicine" and a column were added. Four new CQs were added related to risk factors "diabetes", "intraductal papillary mucinous neoplasms", "chronic pancreatitis" and "genetic risks", which had been discussed in "general statements" in the previous edition. A column on "role of the medical checkup for the diagnosis of pancreatic cancer" was also added. Two previous CQs related to "contrast-enhanced computed tomography" were described in "general statements" as universally acknowledged concepts in the new edition. The diagnostic strategy in the new edition clarified that transabdominal ultrasonography is the first step for evaluation although it is limited for imaging the whole pancreas. A previous CQ for "general pathological diagnosis" was described in "general statements" as a background question, while two CQs on "transabdominal ultrasound guided fine needle biopsy" and "needle biopsy for the diagnosis of gene mutations" were added to the new edition.
